Firebrick Pharma’s US launch of Nasal Spray is nothing to be sneezed at
Australian pharmaceutical developer, Firebrick Pharma (ASX:FRE) has launched its latest product, Nasodine…
Firebrick Pharma Limited (ASX:FRE)
About Firebrick Pharma Limited
Key Information
FRE In the News
ASX Announcements
| Date | Announcement | File | Views |
|---|---|---|---|
| 23/04/2024 | Cleansing Notice | 230.2KB | 146 |
| 23/04/2024 | Application for quotation of securities - FRE | 15.6KB | 147 |
| 23/04/2024 | Price Sensitive PS March 2024 Quarterly Activity Report & Appendix 4C | 346.54KB | 1.0K |
| 17/04/2024 | Price Sensitive PS Nasodine Nasal Spray Launch in the USA | 1.11MB | 9.2K |
| 02/04/2024 | Nasodine Phase 2 COVID-19 Trial Results Published | 158.46KB | 366 |
| 28/03/2024 | Becoming a substantial holder | 312.23KB | 1.1K |
| 04/03/2024 | Nasodine COVID-19 Patent Allowed in US | 144.92KB | 554 |
| 28/02/2024 | Price Sensitive PS Appendix 4D & Half-Year Financial Report to 31 December 2023 | 1.09MB | 3.1K |